Medpace(NASDAQ) MEDP

Medpace helps biotechnology and drug companies bring new medical treatments to market. It manages complex clinical trials to test if new medicines are safe and effective. The company serves as a specialized partner for smaller firms that need expert help with global research.

The Clinical Development Menu

• Full-Service Clinical Trials: Comprehensive management of Phase I through Phase IV studies, which are the different stages of testing drugs in humans to ensure safety and efficacy.
• Medical and Regulatory Affairs: Expert guidance for designing study plans and submitting documentation to global health agencies like the FDA.
• Laboratory Services: Specialized testing through central, bioanalytical, and core laboratories to analyze patient samples and imaging data during trials.
• Clinical Pharmacology: Early-stage testing in healthy volunteers to study how the human body processes and reacts to new drug candidates.

Recent Strategic Moves

• Expanded the Central Laboratory footprint across four global locations, including Cincinnati, Ohio; Leuven, Belgium; Shanghai, China; and Singapore.
• Maintained a focus on organic growth by hiring and developing internal talent, with 75% of management roles filled by internal candidates between October 2024 and September 2025.
• Invested in a global learning management system to standardize regulatory compliance and technical training across 46 countries.

What Makes Medpace Different

The company uses a disciplined, full-service model that keeps all aspects of a clinical trial under one roof to improve speed and quality. This approach relies on its proprietary ClinTrak software, which gives customers real-time data and oversight of their medical studies.

By the Numbers

• Revenue reached $708.5 million in Q4 2025, a 32% increase compared to the same period in 2024.
• Net income rose to $135.1 million in Q4 2025, up 15.5% from Q4 2024.
• Operating income grew to $153.3 million in Q4 2025, representing a 22.2% increase year-over-year.
• Free cash flow was $188.1 million in Q4 2025, up 2.8% from the previous year.
• The company grew its workforce to approximately 6,200 employees across 46 countries by the end of 2025.

Bottom Line

Medpace has evolved into a global clinical research partner with a specific focus on small and mid-sized biopharmaceutical companies. Its centralized operating model and proprietary technology support a steady expansion across major therapeutic areas like oncology and cardiology.